SOUTH SAN FRANCISCO, Calif., Sep 09, 2010 (BUSINESS WIRE) --

Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael M. Morrissey, PhD, the company's president and chief executive officer, will present at the following two investor conferences during the month of September 2010:

• The Stifel Nicolaus 2010 Healthcare Conference in Boston. Dr. Morrissey will present at 9:45 a.m. EDT / 6:45 a.m. PDT on Friday, September 17, 2010.
• The UBS Global Life Sciences Conference in New York. Dr. Morrissey will present at 3:00 p.m. EDT / 12:00 p.m. PDT on Wednesday, September 22, 2010.

During each presentation. Dr. Morrissey will discuss the company's corporate strategy, development pipeline and financial outlook, and provide a general business update.

The events will be webcast and may be accessed in the Event Calendar page under Investors and Media at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE: Exelixis, Inc.

Investor Contacts:
Charles Butler
Vice President,
Investor Relations
and Corporate Communications
Exelixis, Inc.
(650) 837-7277
cbutler@exelixis.com
or
DeDe Sheel
Associate Director,
Investor Relations
Exelixis, Inc.
(650) 837-8231
dsheel@exelixis.com